[Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 23(2): 596-600, 2015 Apr.
Article
in Zh
| MEDLINE
| ID: mdl-25948232
ABSTRACT
Invasive fungal disease (IFD) causes a high morbidity and mortality in patients with hematological malignancies. Reactivation of IFD after chemotherapy or hematopoietic stem cell transplantation (HSCT) is very common and associated with poor prognosis. Secondary antifungal prophylaxis (SAP) is effective in preventing IFD recurrence. With effective SAP, a history of IFD is not an absolute contraindication to allogeneic HSCT or continuation of high-dose chemotherapy. In recent years, a variety of antifungal drugs such as voriconazole, itraconazole, AmB and caspofungin have been found to be effective for SAP. However, its management during granulocytopenia and immunosuppression remains challenging. This review summarizes the current status of SAP in patients with hematological malignancies.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
Mycoses
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhongguo Shi Yan Xue Ye Xue Za Zhi
Journal subject:
HEMATOLOGIA
Year:
2015
Document type:
Article
Affiliation country:
China
Publication country:
CHINA
/
CN
/
REPUBLIC OF CHINA